James E. Flynn and Deerfield Entities Decrease Stake in BiomX Inc. to 8.09%

On May 28, 2026, James E. Flynn and several Deerfield-affiliated entities filed Amendment No. 6 to their Schedule 13D for BiomX Inc. (PHGE). The filing reports a decrease in aggregate beneficial ownership to 889,928 shares, representing 8.09% of the company, down from a previous 9.99%. The reporting period involved multiple transactions. On May 27, 2026, Deerfield Private Design Fund V and Deerfield Healthcare Innovations Fund II each exercised Amended and Restated Warrants for 66,242 shares of Common Stock in cash. On May 28, 2026, each fund converted 47,957 shares of Series X Preferred Stock into 252,397 shares of Common Stock. However, these increases were offset by open-market sales; specifically, on May 27, 2026, both funds sold 49,556 shares each at a weighted average price of $1.4624. James E. Flynn maintains shared voting and dispositive power over these holdings as the sole manager of the general partners of the involved Deerfield entities.